pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1231 |
Genomic Coordinates | chr1: 201808611 - 201808702 |
Synonyms | MIRN1231, hsa-mir-1231, MIR1231 |
Description | Homo sapiens miR-1231 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1231 | |||||||||||||||
Sequence | 5| GUGUCUGGGCGGACAGCUGC |24 | |||||||||||||||
Evidence | Experimental | |||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
|||||||||||||
SNPs in miRNA |
|
|||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | PHLPP2 | ||||||||||||||||||||
Synonyms | PHLPPL, PPM3B | ||||||||||||||||||||
Description | PH domain and leucine rich repeat protein phosphatase 2 | ||||||||||||||||||||
Transcript | NM_015020 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on PHLPP2 | |||||||||||||||||||||
3'UTR of PHLPP2 (miRNA target sites are highlighted) |
>PHLPP2|NM_015020|3'UTR 1 CTGCCCCACTGGGCACAGTGTGGGAGGAGGCTGTGCAGGGTTGGGGTAGGGACTTGCTAGAGGCATTCTGCCTCTACATT 81 TCTTTTTGTTTGTTCGTTTTTTTTTTGTTTGTTTGTTTTGAGACGGAGTCTTGCTCAGTCGCTCAGGCTGGAGTGCAATG 161 GTGGGGTCTCGGGTCACTGCAGCCTCTGTCCCTGGGTTCAAGCCATTCTCCTGTCTCAGCCTCCCGAGTAGCTGGGATTA 241 CAGGCACCTGCCATTATGCCCGGCTAAGTTTTATTTTTTTTTTTTAGAGACGGGGTTTCACCATGTTGGCCAGGCTGGTG 321 TTGAACTCTTGACCTCAGGTGATCCACCCTCCTCTGCCTCCCAAAGTGCTGTGATTACAGGCCTCAGCCACCATGCCCAG 401 CCCTGCGTCTACATTTCTAAACCATAGCTGTGTGGGGTTGAACTCGGAGCCAAAAAGTGTGAGAGCCATCAGGGGCTGGC 481 TCTGGATAAACTGGTAGCCACTATCAGTGTTAAGTTTCACATTTAACCTGCATTGGAATTCCCAGGGGTACTGGGAAGAA 561 AGCAGCTGTTCTGTATCAGTCCTACCACCTGCCATTAACCCTTTCTCTCCTAGGATCATTTTGAGAATTTGCCTGCCTGG 641 GCAGGAAAGGGACTATTTCTGTGGAGGAAAAAAGTGAAGATTGATTCTCTTTACTAGTTGCTGCTGATGGATCTCTGTGA 721 CAGAGAAATCACCTTATCTCAGACTAATGGGGTGTGATGTGACTAGTCACATGGCTTTTCATTCTTCTCTACGAGAATAC 801 AGCCTATCAAAATGATGTCTGTTGGAAATGTAGAACCAATCAAACAGATAATTTATGTATGTAATGTAATGAGAGCACTT 881 TTCATTGACTGTGAACTTTTTATTTTTGAATCTGCACTCGAGCCAATCTTCTTAGAGGCAGCCCGGCACCTTCATCCATA 961 GGCAGAGAGAGAACTGGGTGTTGGAGACTTATTCGAGGGTATAGGAAGGGCCCTGTGAAGTTGATTTAACTTTTGGATGT 1041 CAGACTGTGAAAGCTCCTGAGAAACTTGGGGTAATAGGATCTTCTTTTGGGGATGAAAATGGGGAAGGCGTGAGGACCTA 1121 GACTACTTCTCCCTAGATCAGAAAAAGAGAATTACCCCTTGACAAATATGATACCTGCTAGGTATTTCCCAGGGAAATTT 1201 AGGGATTGGCGTCTTTCCCTAGCATGTGGAGGAATTGGCAGACAGCTTCCTAAGGGCGGGGAGCGGGGGCCCAAGGCTGA 1281 CACTGCTTGCATCCACGTGACCTTAAGTTATGGCAGATGACTCTGAAACGGACTGAGGCCAATGAGAACAGATGGATGGA 1361 GCACTCAGGTTAGACTTGTTCCTTCTCCTATGCTGGAGGAGAGGGATGGTTCTCTAGAATGTTGGAGGTGAGTTGAGAGC 1441 TCGCCTCTTGAATGTTGAACAGTGTACTCTTCTGAAAACTGCATATTCACTTTATGTGGTTTCAGAATACTGGGCTCAAT 1521 ACTAACATAAGAAAGACACTTCATTGAGAAATTCTTAAGCTTACAGAAAACCTATACTCTTTGCACATTCCACATAACCC 1601 TAGCAAAATGCAGTTTCTTCATACTTCTGTCACTTTTTCCATTGGAAGATTTGCTTAGGAAAATTAATTCCTATTTATTC 1681 CCACAAAATGTTGGCATTGCTTGATTTTACCCAATGGGGAATGTGCTTTGAATTTTTGGAACACTTTTACAATTAAAAAT 1761 AAAGTAGGGCCATTTTTAATTTGTTTCATCAGAAACTATGTTAAAGAGAGGGTTAAATATAAATATATTTTCGTGTGTAT 1841 TTTTGGGAAGATTTTTGTTCAAAGCAATAGTCAAAATCAGATGACCTGTCCATAATAATTATGTGTCTTCATCTTCTCAG 1921 AGGCCCCATGCTCATATGCACGTGTCATTGGGATACACTCTTGGGGGATTTGGTACACTCTAATGGATGTCTAATGTTCA 2001 ACCCCTCGAGAATCTGAACTTGAGTCCCCAGATTGTCAAACTACTGGTCAGCTATTGAGAATTTTAGAACTCAGGTCTTT 2081 GATTTGAAGTAGGGAACATAGTGGCTCACACAGAGTTTAGGTGCTGTTAGAAAGATGGGAACAAGAGTGTTTTGCCACCT 2161 TATTTTTATATGGGAAATTTTTTTTAATGAAGAAAAAATGAAAATGAAATAACAGGATGATAGTGATGAGTGATGTAAAA 2241 CATCTTACTTAGATGGCAGAACCTTCGGGTTGTAGAATAGTGATGTCTAAAAATTAAAGTTATTTTGGGAATACACCACT 2321 TTAATAGTATAGTCTTATAAAAATTATTCATTATGGTGAACCCTTCTTGTCTGCTATTCGTTTCCCAACCTACTTATTGG 2401 AACCACCTCAAAACCCAGTTCTGAAATGACCTTACCAAAAGTAAATGTATTTATTTTTTAGTCAGCAGAACTCTGTAATT 2481 CCAAATGTTGTTCTGTGTGGTAGAATTTTTTTTCAGGAACCATTAGGTTGTATTGAAAATCTTTGTTATAGGCGATACCA 2561 AAACTGATTATTCTTTTTTGCAGTCTGCTTTAATTCATGTCCTTCTGCAGTTGCTCTGTATTAAAACAGGGTAAAAAGGC 2641 CATAGCCCATTATGAAAAATATAATACAAAACTCTTTGACCTATGAGGTAACTTACAGACATTGTGTTTTCTAAACAGGC 2721 TGTCAGTGAAAGCCCGTATCTGTCTCCAGGTGAATGTAATTTACTTCCGAGTACTTTACCCAGAGGATGTGTTCCCCAGG 2801 TGGGCAGAGTACAGTTGATCTCTAGCACAGACAGAGATTCTGGCCTCTGCATATTCTCAGGTCTCTGTGTGTACCTCCCA 2881 TTGAGTAGAGAAGCTTAAGATAATTTCTGAGAGAAGAACACTGCTGATTGTGGGAGCAGTTTAGGAGTCCATGGAAGAAA 2961 GAAAAATACATGTGTCTTGGCAGCCATGGTGTATTTTTGTCCAAATGGATTGGAAGGATATTTGAATATTTGAATGTTGG 3041 TATGACATAAAGCTGCAGTGCACTATAGAGTCAAGTCATTGAATTACCACTCCTGATACAGGGCTTTATTGTACTACTGT 3121 GAAGTGTATGTGTGCAATACATTGGTGAGTTCATTTACTGGTGTACGGAAGAGCCAGCAGGAGCAGCGTGGTCATTGCTG 3201 GGTGCTATTACAGTTGCTTGTAGTGAGTGCTGTTTTCCAGGAGATGGAGCCAGTTGGGTGTGGCAGATCTACTGAATATC 3281 AAATGATGCTCTTCTTCCCATGTAGACCTTCAGCAAAAGCCGGTACTTGGAAGCCACAGGCTCACCTTCTCTATCTATCC 3361 AATAATTATTAATGAAGAGACCTCCATAAGGGAGCAGCTGGCTGTTATCGATAAATGTACCAATTATTAAATAATTAGTC 3441 TCCAAGCCATTCAGTGATGTCTTCAGCATCACTATAGGACTGTCTAGTGTCACTTTTTACTTCCTTCTGGGTGGAGGCTT 3521 TCCGACTCCCAATCATGAAGGCAAGTTAATCTTTCCAGTTAGTGACTTTTGCCCCATAGTTGGGGTAAGCACTTCCTAGA 3601 TTGAGAAAAAGCAGCTACAGTCAATCCTGCTCTGTTTGCCTCATTTGGTGATCAGTCAGTCACACATAAGTTCCTTGTAT 3681 TCTAAATTTCATGCACTTCTCCCAGATGCTATAGGGTTTTCTCTCACTGTTGCCAGTGGATGTCATCCAGACAGTGGGCT 3761 CATATCTTACGGTTTTGTGCAATCATTGTCGTATTGTAGTCTTAAGACTCATTATAGTGTATTTTTGATATTTTTGAAAT 3841 GTGTTAAATTTTTTAATTCAATAATATGAGCCAGAGCATGTTGCAGCAAATCTATTGTTTGTAAAAATAACAATAACAAT 3921 AATAAATAAAATAAAGTGGAATCTTTTTCATGGCTTTGTTTTAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
miRNA:Target | ---- | |||||||||
Validation Method |
|
|||||||||
Conditions | HEK293 | |||||||||
Disease | 23035.0 | |||||||||
Location of target site | 3'UTR | |||||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | |||||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM714644. RNA binding protein: AGO2. Condition:completeT1
... - Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods. |
|||||||||
miRNA-target interactions (Provided by authors) |
|
|||||||||
Article |
- Kishore S; Jaskiewicz L; Burger L; Hausser et al. - Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
|
CLIP-seq Support 1 for dataset GSM714644 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repA |
Location of target site | ENST00000568954.1 | 3UTR | ACAGUGGGCUCAUAUCUUACGGUUUUGUGCAAUCAUUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
37 hsa-miR-1231 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT075228 | PHF13 | PHD finger protein 13 | 2 | 6 | ||||||||
MIRT266936 | HDGF | heparin binding growth factor | 2 | 6 | ||||||||
MIRT441394 | SOX5 | SRY-box 5 | 2 | 2 | ||||||||
MIRT446329 | ATP5C1 | ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 | 2 | 2 | ||||||||
MIRT446438 | THYN1 | thymocyte nuclear protein 1 | 2 | 2 | ||||||||
MIRT482781 | STIM1 | stromal interaction molecule 1 | 2 | 2 | ||||||||
MIRT497714 | CYP1A1 | cytochrome P450 family 1 subfamily A member 1 | 2 | 2 | ||||||||
MIRT500907 | STARD13 | StAR related lipid transfer domain containing 13 | 2 | 2 | ||||||||
MIRT503251 | KIF18B | kinesin family member 18B | 2 | 2 | ||||||||
MIRT504750 | TEP1 | telomerase associated protein 1 | 2 | 4 | ||||||||
MIRT512158 | CD164 | CD164 molecule | 2 | 6 | ||||||||
MIRT518043 | LSM3 | LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated | 2 | 4 | ||||||||
MIRT526038 | GMDS | GDP-mannose 4,6-dehydratase | 2 | 2 | ||||||||
MIRT529828 | ARGFX | arginine-fifty homeobox | 2 | 2 | ||||||||
MIRT531808 | POLD3 | DNA polymerase delta 3, accessory subunit | 2 | 2 | ||||||||
MIRT533139 | WNT10A | Wnt family member 10A | 2 | 2 | ||||||||
MIRT538612 | CCT5 | chaperonin containing TCP1 subunit 5 | 2 | 4 | ||||||||
MIRT555617 | PHLPP2 | PH domain and leucine rich repeat protein phosphatase 2 | 2 | 2 | ||||||||
MIRT561705 | PTP4A1 | protein tyrosine phosphatase type IVA, member 1 | 2 | 2 | ||||||||
MIRT562301 | GINM1 | glycoprotein integral membrane 1 | 2 | 2 | ||||||||
MIRT566732 | MSH6 | mutS homolog 6 | 2 | 2 | ||||||||
MIRT569369 | IMPG1 | interphotoreceptor matrix proteoglycan 1 | 2 | 2 | ||||||||
MIRT572314 | HSPB6 | heat shock protein family B (small) member 6 | 2 | 2 | ||||||||
MIRT574602 | LZIC | leucine zipper and CTNNBIP1 domain containing | 2 | 2 | ||||||||
MIRT612023 | FOXF2 | forkhead box F2 | 2 | 2 | ||||||||
MIRT616950 | MAPKAPK2 | mitogen-activated protein kinase-activated protein kinase 2 | 2 | 2 | ||||||||
MIRT624175 | DERL2 | derlin 2 | 2 | 2 | ||||||||
MIRT647634 | FAIM2 | Fas apoptotic inhibitory molecule 2 | 2 | 2 | ||||||||
MIRT659393 | CORO2A | coronin 2A | 2 | 2 | ||||||||
MIRT659955 | CXCL10 | C-X-C motif chemokine ligand 10 | 2 | 2 | ||||||||
MIRT684001 | FOLR1 | folate receptor 1 | 2 | 2 | ||||||||
MIRT688143 | GABPB1 | GA binding protein transcription factor beta subunit 1 | 2 | 2 | ||||||||
MIRT688609 | CYBRD1 | cytochrome b reductase 1 | 2 | 2 | ||||||||
MIRT693583 | SLC39A1 | solute carrier family 39 member 1 | 2 | 2 | ||||||||
MIRT699922 | RUFY2 | RUN and FYVE domain containing 2 | 2 | 2 | ||||||||
MIRT712961 | PET117 | PET117 homolog | 2 | 2 | ||||||||
MIRT723950 | TMEM184A | transmembrane protein 184A | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|